Consensus Alkermes plc

Stocks

ALKS

IE00B56GVS15

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 17:45:29 04/09/2026 +03			5-day change	1st Jan Change
46.52 ^USD	-0.78%		-1.88%	+66.26%

10:39am	After obesity, pharma seeks its next mega-blockbuster in sleep
08-25	Alkermes plc Publishes Data From Vibrance-1 Phase 2 Study Of Alixorexton In Adults With Narcolepsy Type 1	CI

Evolution of the Average Target: Alkermes plc

Evolution of the Target Price: Alkermes plc

Changes in Analyst Recommendations: Alkermes plc

59d5c35bdf876e6d9ff6a38bfec94._EnDfu5FOmeYYV5rk-8ga4KyZslXXwrUPOEn134K48o.vhqbL5snTyLeIDoP1ZdmKcTAMZ8TGHiWD6547yldkv2VDbEmvwpNLftZPQ~b7f5e40d4749d8e5de930781db6cb708

Analysts' recommendations: Alkermes plc

07-29	Alkermes' Core Business Backed Q2 Beat, Orexin Pipeline to Serve as Catalyst, RBC Says	MT
06-29	Alkermes Faces Risk on Orexin-Related Value From Upcoming Updates, BofA Says	MT
06-29	BofA Securities Downgrades Alkermes to Underperform From Neutral, $38 Price Target	MT
06-22	Deutsche Bank Lifts Alkermes Price Target to $60 From $47, Maintains Buy Rating	MT
06-09	Alkermes' Orexin May Have Applicability Outside Sleep, RBC Says	MT
06-09	RBC Raises Price Target on Alkermes to $56 From $45, Keeps Outperform Rating	MT
05-06	Alkermes' Q1 Revenue Beat Highlights 'Underappreciated' Core Business, RBC Says	MT
05-06	UBS Adjusts Price Target on Alkermes Public to $48 From $42, Maintains Buy Rating	MT
04-09	BofA Adjusts Price Target on Alkermes Public to $36 From $34, Maintains Neutral Rating	MT
04-07	RBC Capital Adjusts Price Target on Alkermes Public to $44 From $45, Maintains Outperform Rating	MT
02-26	RBC Lowers Price Target on Alkermes to $45 From $47, Keeps Outperform Rating	MT
02-18	Deutsche Bank Adjusts Alkermes Price Target to $42 From $43, Maintains Buy Rating	MT
11-19	Alkermes Faces Pressure to Secure the Buyout of Avadel After Lundbeck's Unsolicited Bid, RBC Says	MT
11-17	Truist Raises Price Target on Alkermes to $55 From $50, Keeps Buy Rating	MT
11-13	Deutsche Bank Lowers Price Target on Alkermes to $45 From $55, Keeps Buy Rating	MT
11-11	Truist Initiates Alkermes at Buy With $50 Price Target	MT
29/10/25	Deutsche Bank Adjusts Alkermes Price Target to $55 From $53, Maintains Buy Rating	MT
23/10/25	RBC Raises Price Target on Alkermes to $47 From $45, Keeps Outperform Rating	MT
08/10/25	RBC Lifts Price Target on Alkermes to $45 From $44, Keeps Outperform Rating	MT
26/09/25	Alkermes' Stock Dip on Narcolepsy Data Seen as Buying Opportunity, RBC Says	MT
26/09/25	RBC Capital Upgrades Alkermes to Outperform From Sector Perform, Adjusts PT to $44 From $42	MT
03/09/25	Wells Fargo Initiates Alkermes Public at Overweight With $44 Price Target	MT
30/07/25	RBC Raises Price Target on Alkermes to $42 From $40, Keeps Sector Perform Rating	MT
17/06/25	UBS Upgrades Alkermes Public to Buy From Neutral, Adjusts Price Target to $42 From $33	MT
28/05/25	Needham Initiates Alkermes Public at Buy With $45 Price Target	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ALKERMES PLC					+19.45%
	LONZA GROUP AG					+17.72%
	REVOLUTION MEDICINES, INC.					+17.98%
	IQVIA HOLDINGS INC.					+1.71%
	BEONE MEDICINES AG					+19.16%
	CELLTRION, INC.					+42.19%
	ASCENDIS PHARMA A/S					+15.78%
	MEDPACE HOLDINGS, INC.					-1.95%
	EUROFINS SCIENTIFIC SE					-1.27%
	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.					-4.21%
	Average					+12.66%
	Weighted average by Cap.					+15.02%